News

Deal Announcements

Aduro BioTech Accepts $55 Million Venture Capital

Thursday, June 13, 2013 5:45:00 AM PDT | VentureDeal
   Berkeley, CA  --  Biotechnology company Aduro BioTech has raised $55 million in its third round of venture capital funding.

Aduro is developing a platform of attenuated and targeted vaccines based on Listeria monocytogenes.

Johnson & Johnson Dev. Corp., Morningside Group and others made the investment.

The company will use the funding to advance its lead program in metastatic pancreatic cancer treatment and other pipeline advancements.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1